title: [Effects of intravenous administration of clarithromycin on plasma levels of gastrin and group I pepsinogen].
abstract: Erythromycin and some of its derivatives have prokinetic gastrointestinal properties. In addition, erythromycin has been shown to stimulate isolated chief cells of the gastric mucosa, and to activate pepsin secretion. The above study was aimed at ascertaining in a group of dyspeptic patients whether clarithromycin, a structural analogue of erythromycin, is apt to modify certain functional parameters of gastric secretion, above all the patterns of gastrin and PG-I secretion. A 20-minute intravenous clarithromycin infusion (1.5 mg/kg) in fasting subjects has brought about a significant reduction (at 20 and 45 minutes from the start of infusion) of circulating gastrin (about 23%) and, after a meal, a 69% increase. No change of plasma PG-I level was observed either after placebo or after the active substance. These findings suggest that in vivo and at the doses used in our experiment clarithromycin has no influence on plasma PG-I release and is apt to modify the fasting and postprandial gastrin releasing pattern.
authors: Cattedra di Gastroenterologia, Università degli Studi di Messina.
authors: S
authors: S
authors: Pustorino
authors: S
authors: S
authors: Turiano
authors: C
authors: C
authors: Pizzimenti
authors: G
authors: G
authors: Calipari
authors: G
authors: G
authors: Federico
authors: G
authors: G
authors: D'Amico
authors: C
authors: C
authors: Sinopoli
authors: P
authors: P
authors: Martinez
authors: O
authors: O
authors: Guerrisi
authors: G
authors: G
authors: Luzza
mesh_terms: D000328:Adult; D000368:Aged; D017291:Clarithromycin / Q000008:administration & dosage / Q000494:pharmacology*; D004415:Dyspepsia / Q000097:blood; D005260:Female; D005755:Gastrins / Q000097:blood*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010435:Pepsinogens / Q000097:blood*
chemical_list: D005755:Gastrins; D010435:Pepsinogens; D017291:Clarithromycin
vernacular_title: Effetti della somministrazione venosa di claritromicina sui livelli plasmatici di gastrina e pepsinogeno del gruppo I.